Zymeworks BC Inc ZYME

NAS: ZYME | ISIN: US98985Y1082   14/11/2024
16,26 USD (-5,52%)
(-5,52%)   14/11/2024

5 november 2024 · Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors · Persbericht

29 oktober 2024 · Zymeworks Announces Participation in Upcoming Investor Conferences · Persbericht

25 oktober 2024 · Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference · Persbericht

21 oktober 2024 · Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers · Persbericht

18 september 2024 · Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference · Persbericht

22 augustus 2024 · Zymeworks Announces Participation in Upcoming Investor Conferences · Persbericht

1 augustus 2024 · Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock · Persbericht

25 juli 2024 · Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer · Persbericht

22 juli 2024 · Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate · Persbericht

11 juli 2024 · Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024 · Persbericht

17 juni 2024 · Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers · Persbericht

10 juni 2024 · Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer · Persbericht

28 mei 2024 · Zymeworks Announces Participation in Upcoming Investor Conferences · Persbericht

2 mei 2024 · Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results · Persbericht

30 april 2024 · Zymeworks Announces Participation in Upcoming Investor Conferences · Persbericht

8 april 2024 · Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting · Persbericht

28 maart 2024 · Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors · Persbericht

27 maart 2024 · Zymeworks Announces Participation in Upcoming Investor Conferences · Persbericht

5 maart 2024 · Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting · Persbericht

27 februari 2024 · Zymeworks Announces Participation in Upcoming Investor Conferences · Persbericht

Mijn selecties